India is participating in the NeoSep1 clinical trial, which aims to improve treatment for drug-resistant newborn sepsis using ...

Jipmer becomes the first Indian center to enroll an infant in the NeoSep1 trial, targeting neonatal sepsis and antimicrobial resistance.

Sepsis leads to life-threatening organ failure due to dysregulated host responses to infection and presents uniquely across age groups. Neonatal sepsis, affecting infants in their first 28 days, ...

A major multi-country study has found that WHO-recommended first-line antibiotics for neonatal sepsis are likely to be effective in only one-quarter of infections in low- and middle-income countries ...

India has enrolled its first newborn in the global NeoSep1 trial at JIPMER, Puducherry. The study will test antibiotic combinations for neonatal sepsis as resistance weakens standard treatments.

LISBON, Portugal — A shift toward broader-spectrum antibiotics and increasing antibiotic resistance has led to high levels of mortality and neurodevelopmental impacts in surviving babies, according to ...

Each year, sepsis affects more than 30 million people worldwide, causing an estimated six million deaths. Sepsis is the body's extreme response to an infection and is often life-threatening. Since ...

This may sound like an intimidating technical topic, but I’m going to keep it simple. I went to public schools, so I’m going to leave the complicated math to MIT graduates.[2] Before I dive into the ...

Early-onset neonatal sepsis and meningitis are associated with an increased risk of developing cerebral palsy in infants born at or near term.